Last reviewed · How we verify
NCT06735703
Group B Streptococcus Infection and PROM Incidince
trial testing To provide ampicillin sulbactam to pregnant women with premature rupture of membrane in Premature Rupture of Fetal Membranes in 150 participants. Not yet recruiting.
9 December 2025
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 25 December 2024 |
| Primary completion | 9 December 2025 |
| Estimated completion | 9 January 2026 |
Drugs / interventions tested
- To provide ampicillin sulbactam to pregnant women with premature rupture of membrane — full drug profile →
Conditions studied
- Premature Rupture of Fetal Membranes — all drugs for Premature Rupture of Fetal Membranes →
- Group B Streptococcal Infection — all drugs for Group B Streptococcal Infection →
Sponsor
Assiut University
Who can join
Eligibility, female only, with Premature Rupture of Fetal Membranes or Group B Streptococcal Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To investigate incidince of prom with GBS infection and role of prophylaxis against it
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06735703
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06735703 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 16 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06735703.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing